U.S. Antidiabetics Market, 2026-2033
- Pharmaceuticals
- Metabolic Disorders Treatment
- antidiabetics market
- Metabolic Disorders Treatment
Global Market
Related Markets
Ask Prism AI about the antidiabetics market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
U.S. antidiabetics market highlights
- The U.S. antidiabetics market generated a revenue of USD 39,805.3 million in 2025 and is expected to reach USD 89,269.1 million by 2033.
- The U.S. market is expected to grow at a CAGR of 10.3% from 2026 to 2033.
- In terms of segment, glp-1 receptor agonists was the largest revenue generating drug class in 2025.
- GLP-1 Receptor Agonists is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antidiabetics market data book summary
| Market revenue in 2025 | USD 39,805.3 million |
| Market revenue in 2033 | USD 89,269.1 million |
| Growth rate | 10.3% (CAGR from 2026 to 2033) |
| Largest segment | Glp-1 receptor agonists |
| Fastest growing segment | GLP-1 Receptor Agonists |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors |
| Key market players worldwide | AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Boehringer Ingelheim, Bristol-Myers Squibb Co, Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG ADR |
Other key industry trends
- In terms of revenue, U.S. accounted for 38.3% of the global antidiabetics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. antidiabetics market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 7,999.6 million by 2033.
The U.S. antidiabetics market is projected to witness sustained growth during the forecast period. This is attributed to advancements in clinical research, an increasing number of FDA-approved drugs, and a robust pipeline of ongoing R&D.
The increasing focus on personalized diabetic therapy and improved access to newer drug classes is also supporting market growth. As of mid-2022, nearly 100 antihyperglycemic agents were under evaluation for type 2 diabetes, and over 60 had already received approval, underscoring the dynamic development landscape.
No credit card required*
Publish Date: Apr 14, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antidiabetics Market
Antidiabetics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
U.S. antidiabetics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Antidiabetics Market will help companies and investors design strategic landscapes.
Glp-1 Receptor Agonists was the largest segment with a revenue share of 57.94% in 2025.
Horizon Databook has segmented the U.S. antidiabetics market based on insulin, glp-1 receptor agonists, dpp- 4 inhibitors, sglt2 inhibitors covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. antidiabetics market is projected to witness sustained growth during the forecast period. This is attributed to advancements in clinical research, an increasing number of FDA-approved drugs, and a robust pipeline of ongoing R&D.
The increasing focus on personalized diabetic therapy and improved access to newer drug classes is also supporting market growth. As of mid-2022, nearly 100 antihyperglycemic agents were under evaluation for type 2 diabetes, and over 60 had already received approval, underscoring the dynamic development landscape.
- U.S. Antidiabetics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Insulin
- GLP-1 Receptor Agonists
- DPP- 4 Inhibitors
- SGLT2 Inhibitors
- Others
- U.S. Antidiabetics Market Diabetes Type Outlook (Revenue, USD Million , 2021-2033)
- Type 1
- Type 2
- U.S. Antidiabetics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.S. Antidiabetics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Subcutaneous
- Intravenous
Reasons to subscribe to antidiabetics market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of antidiabetics market databook
- Our clientele includes a mix of antidiabetics market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. antidiabetics market, including forecasts for subscribers. This country databook contains high-level insights into U.S. antidiabetics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Antidiabetics Market, 2021-2033 (US$M)
U.S. antidiabetics market statistics, by drug class, 2021-2033 (US$M)
